Opinion|Videos|October 29, 2025
Leveraging Real-World Evidence in Sequencing Decisions for mCRC
Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.
Advertisement
Episodes in this series
Panelists explain that in the absence of head-to-head trial data, real-world evidence (RWE) becomes crucial in guiding sequencing decisions between agents such as trifluridine/tipiracil, fruquintinib, and regorafenib.
They highlight how RWE provides insights into treatment outcomes across broader and more diverse patient populations than those typically seen in clinical trials.
This information allows clinicians to refine sequencing strategies, especially when balancing efficacy and tolerability for patients in later-line settings.
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5